Targeted endometrial cancer therapy as a future prospect

Keyphrases

• Cancer Therapy 100%
• Endometrial Cancer 100%
• High Risk 33%
• Progression-free Survival 33%
• Europe 33%
• Overall Survival 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Tyrosine Kinase 33%
• Breast Cancer 33%
• Advanced Disease 33%
• Obesity 33%
• EGF Receptor 33%
• Aging Population 33%
• Postmenopausal Women 33%
• FGF Receptor 33%
• Cervical Cancer 33%
• Gynecological Cancer 33%
• Targeted Molecular Therapy 33%
• Intermediate Risk 33%
• Adjuvant Chemotherapy 33%
• Intraoperative Radiation Therapy 33%
• Recurrent Cancer 33%
• Advanced Cancer 33%
• Possible Treatments 33%
• Locoregional Recurrence 33%
• Molecular Features 33%
• Female Cancer 33%
• Human EGF 33%
• Treatment Candidates 33%

Medicine and Dentistry

• Cancer Therapy 100%
• Uterine Cancer 100%
• Diseases 100%
• Cancer 33%
• Progression Free Survival 33%
• Overall Survival 33%
• Protein Tyrosine Kinase 33%
• Advanced Cancer 33%
• Postmenopause 33%
• Breast Cancer 33%
• Cervical Cancer 33%
• Recurrent Disease 33%
• Epidermal Growth Factor Receptor 33%
• Molecularly Targeted Therapy 33%
• Female Genital Tract Cancer 33%
• Vasculotropin 33%
• Adjuvant Chemotherapy 33%
• Tamoxifen 33%
• Cancer Recurrence 33%
• Mammalian Target of Rapamycin 33%
• Fibroblast Growth Factor Receptor 33%
• Radiation Therapy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Endometrium Cancer 100%
• Diseases 100%
• Progression Free Survival 33%
• Overall Survival 33%
• Chemotherapy 33%
• Protein Tyrosine Kinase 33%
• Epidermal Growth Factor Receptor 33%
• Breast Cancer 33%
• Recurrent Disease 33%
• Female Genital Tract Cancer 33%
• Fibroblast Growth Factor Receptor 33%
• Cancer Recurrence 33%
• Uterine Cervix Cancer 33%
• Vasculotropin 33%
• Tamoxifen 33%
• Advanced Cancer 33%